Authors


Ling Chen, MD, MPH

Latest:

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.


Ervant J. Maksabedian Hernandez, PhD, MPhil

Latest:

Association of Physician Specialty With Psoriatic Arthritis Treatment and Costs

In this retrospective cohort study of patients with newly diagnosed psoriatic arthritis, the authors examine the association of treatment selection and costs with physician specialty.


Anne Brisendine, DrPH

Latest:

Social Determinants of Health and Emergency Department Utilization in Alabama Children’s Health Insurance Program

Community social determinants of health such as rurality and low socioeconomic status moderate the association between an individual’s race and emergency care use.


Sean P. Fleming, MSW

Latest:

Patterns of Opioid Use in Commercially Insured Patients With Cancer

Among the fewer than half of patients with cancer who received opioid fills, a relatively small proportion (2.5%) had potentially problematic opioid use.


Adam S. Kittai, MD

Latest:

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Experts discuss future directions of BTK inhibitors.


Anjana Sharma, MD

Latest:

Implementing Team-Based Telemedicine Workflows in Safety-Net Primary Care

Telemedicine in safety-net primary care faces particular challenges. Consistent, team-based workflows can support video visit implementation and health care maintenance in telemedicine visits.


Ashley Son, MS

Latest:

Contributor: Patient-Centered Approaches to Supporting Medication Adherence Among Persons With Schizophrenia

There are effective strategies that can be employed concurrently to promote adherence to medications for schizophrenia, including but not limited to pharmacological, technological, and psychosocial interventions.


Quinn Everts

Latest:

How Understanding Risk Factors Can Help Patients With Chronic Diseases Quit Smoking

How much does education about the specific risks of smoking assist in smoking cessation?


R. Scott Leslie, PhD, MPH

Latest:

Scenario Analysis When Conducting Budget Impact Analyses for Rare Diseases

The authors propose conducting a scenario analysis for interventions to treat rare diseases by varying health plan size to demonstrate the variability of potential budget impact.


Ann Marie Huffenberger, DBA, RN, NEA-BC

Latest:

Economics of a Health System’s Direct-to-Consumer Telemedicine for Its Employees

A direct-to-consumer telemedicine service resulted in lower per-episode unit costs for care within 7 days and only marginally increased the use of services overall.


Jeffrey Crowley, MPH

Latest:

Future of PrEP

Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.


Randi Foraker, PhD, MA

Latest:

Using Electronic Health Records and Claims Data to Identify High-risk Patients Likely to Benefit From Palliative Care

Deep learning algorithms could improve palliative care by predicting mortality from electronic health records and claims data.


Alan Gabot, PharmD

Latest:

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.


Denise Tran, PharmD

Latest:

Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration

A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.


Emel Sezer, MD

Latest:

Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer

The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.


Jessi Humphreys, MD

Latest:

Reimagining the Inpatient Palliative Care Consult: Lessons From COVID-19

Digital innovations in palliative care during COVID-19 have changed how hospitalized patients receive palliative care. We propose an approach to implement new models at scale.


Mattijs E. Numans, PhD

Latest:

Identifying Complex Patients Using Adjusted Clinical Groups Risk Stratification Tool

In this study, the authors developed a method for use in primary care to identify a group of patients with complex care needs using Aggregated Diagnosis Groups.


Shelley A. Jazowski, PhD, MPH

Latest:

Association Between Low-Income Subsidies and Inequities in Orally Administered Antimyeloma Therapy Use

Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.


Kristina M. Cordasco, MD, MPH, MSHS

Latest:

Patients’ Needs Following Emergency Care for Ambulatory Care–Sensitive Conditions

To inform intervention development, we assessed for medication changes and patient care needs following treat-and-release Veterans Affairs emergency department visits for chronic ambulatory care–sensitive conditions.


Kristi Rosa

Latest:

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.




Mary Reyes, MD

Latest:

Service Line Care Delivery Model for COVID-19 Patient-Centric Care

The authors provide steps hospitals can take to align their care delivery model to effectively meet the demands of a public health crisis such as the current pandemic.


Ameya Chavan, MS

Latest:

Cost-Effectiveness of a Multicancer Early Detection Test in the US

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.


Chad Cannon, PharmD, BCCCP

Latest:

Private Label Biosimilars

The expert panel discusses the greater potential for private label biosimilars.



Salama Freed, PhD

Latest:

Risk Adjusting for Medicaid Participation in Medicare Advantage

When comparing risk-adjustment approaches based on Medicaid status of Medicare beneficiaries, this analysis found that predicted spending levels varied depending on states’ Medicaid eligibility criteria.


Leah Lovgren, MS

Latest:

Long-Term Health Care Costs Following COVID-19: Implications for Pandemic Preparedness

A difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.


Samuel Moy, BS

Latest:

Variation in Spending Associated With Primary Care Practices

Physician practices account for a significant amount of variation in spending.


Lauretta Dozier, RN

Latest:

Leveraging Longitudinal Clinical Laboratory Results to Improve Prenatal Care

Collaboration between a clinical laboratory and a managed care organization improved prenatal care and outcomes through real-time, actionable, laboratory-derived insights and care coordination.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo